Brokerages Set Genmab A/S (NASDAQ:GMAB) Target Price at $39.17

Genmab A/S (NASDAQ:GMAB) has received an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $39.17.

A number of brokerages have weighed in on GMAB. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reissued a “buy” rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th.

Institutional Trading of Genmab A/S

Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock worth $868,000 after acquiring an additional 3,377 shares during the period. SG Americas Securities LLC boosted its holdings in Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock valued at $551,000 after acquiring an additional 11,949 shares during the last quarter. Blue Trust Inc. boosted its holdings in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the last quarter. Finally, R Squared Ltd bought a new position in Genmab A/S during the 4th quarter worth approximately $93,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

GMAB opened at $20.59 on Thursday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.41. The firm has a market cap of $13.63 billion, a P/E ratio of 11.83, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. The business’s fifty day moving average is $20.47 and its 200-day moving average is $21.04.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.